RCS - OptiBiotix Health - Investor evening <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

06/09/2017 09:30

RNS Number : 9507P
OptiBiotix Health PLC
06 September 2017
OptiBiotix Health plc
("OptiBiotix"or "the Company")
Investor evening
OptiBiotix Healthplc(AIM: OPTI),alifesciencesbusinessdevelopingproducts totackleobesity,high cholesterolanddiabetes, announces that Stephen O'Hara, CEO of Optibiotix,will be presenting at an investor evening hosted by Turner Pope Investments Ltd ("TPI").The event will be held on Tuesday 19 September 2017 in Mayfair, London and will commence at 5pm.
To register your interest and obtain further details, please contact TPI oninfo@turnerpope.comor call 020 3621 4121.
No new material or trading information will be provided.
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix Health PLC - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRASSUSAMFWSESU